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Cellular therapy with dendritic cells (DCs) is emerging as a useful immunotherapeutic 
tool to treat multiple myeloma (MM). DC-based idiotype vaccination was recently sug-
gested to induce idiotype-specific immune responses in MM patients. However, the clin-
ical results so far have been largely disappointing, and the clinical effectiveness of such 
vaccinations in MM still needs to be demonstrated. DC-based therapies against MM may 
need to be boosted with other sources of tumor-associated antigens, and potent DCs 
should be recruited to increase the effectiveness of treatment. DCs with both high mi-
gratory capacity and high cytokine production are very important for effective DC-based 
cancer vaccination in order to induce high numbers of Th1-type CD4
+ T cells and CD8
+
cytotoxic T lymphocytes. The tumor microenvironment is also important in the regulation 
of tumor cell growth, proliferation, and the development of therapeutic resistance after 
treatment. In this review, we discuss how the efficacy of DC vaccination in MM can be 
improved. In addition, novel treatment strategies that target not only myeloma cells but 
also the tumor microenvironment are urgently needed to improve treatment outcomes.
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INTRODUCTION
Multiple myeloma (MM) is a clonal B cell malignant dis-
ease that is characterized by the proliferation of plasma cells 
in the bone marrow (BM) in association with monoclonal 
protein in the serum and/or urine, immune paresis, skeletal 
destruction, renal dysfunction, anemia, hypercalcemia, and 
lytic bone diseases [1]. Although the introduction of 
high-dose therapy with hematopoietic stem cell trans-Korean J Hematol 2012;47:17-27.
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plantation (HSCT) and the development of novel molecular 
targeting agents has resulted in a marked improvement in 
overall survival, MM still remains incurable [2]. Alternative 
approaches are clearly needed to prolong both disease-free 
and overall survival of patients with MM. To prolong the 
survival of patients with MM who are undergoing allogeneic 
HSCT, donor lymphocyte infusion can be used successfully 
as a salvage therapy, based on the graft-versus-myeloma ef-
fect in some cases of MM that relapse after allogeneic HSCT 
[3, 4]. A clinically significant immune-mediated allogeneic 
graft-versus-myeloma effect provides the framework for de-
velopment of immune-based therapeutic options that use 
antigen-presenting cells (APCs), such as dendritic cells (DCs), 
in MM [4, 5].
DCs are the most potent APCs for initiating cellular im-
mune responses through the stimulation of naive T cells. 
Because of their ability to stimulate T cells, DCs act as links 
between innate immunity and adaptive immunity in anti-
tumor immune responses [6]. These DCs play a central role 
in various immunotherapy protocols through generation of 
cytotoxic T lymphocytes (CTLs) [7]. DC-based vaccines have 
become the most attractive tool for cancer immunotherapy 
and have been used in the treatment of more than 20 malig-
nancies [8]. In MM, cellular immunotherapy using DCs is 
emerging as a useful immunotherapeutic modality [8]. Since 
tumor antigen-loaded DCs are expected to be able to stim-
ulate tumor-specific CTLs and to overcome T cell tolerance 
in patients with tumors, the development of DC vaccines 
that can consistently eliminate minimal residual disease re-
mains an important goal in the field of tumor immunology 
[9].
IMMUNE DISORDERS IN MM
Usually, hematologic malignancies elicit weak immuno-
genic responses that are generally incapable of mediating 
tumor destruction. They are able to escape immune surveil-
lance via down-regulation of costimulatory molecules and 
major histocompatibility complex (MHC) molecules as well 
as the production of immunosuppressive cytokines by tumor 
cells or by activation of suppressor cells such as regulatory 
T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) 
[10]. In particular, MM induces immune paresis [11]. Patients 
with MM have DCs that are functionally defective, evidenced 
by the decreased number of circulating DCs and impaired 
T cell stimulatory capacity [12, 13]. Myeloma cells can pro-
duce immuno-inhibitory cytokines, such as interleukin 
(IL)-10, transforming growth factor beta (TGF-β), vascular 
endothelial growth factor (VEGF), and IL-6, which play ma-
jor roles in the pathogenesis of MM, aberrant functions of 
DCs, and impaired development of effector functions in tu-
mor-specific lymphocytes [12, 13]. In addition, the survival 
and proliferation of tumor cells are partially facilitated by 
impaired endogenous immune surveillance against tumor 
antigens, including the abrogation of DC function, by con-
stitutive activation of the signal transducer and activator 
of transcription 3 (STAT3) [14]. Impairment in both humoral 
and cellular immunity in MM is associated with impaired 
B cell differentiation and antibody responses [12]; reduced 
T cell numbers, specifically CD4
+ T cells and abnormal 
Th1/Th2 CD4
+ T cell ratios [15]; impaired CTL responses 
[16]; and dysfunction of natural killer (NK) cells and natural 
killer T (NKT) cells [17, 18]. In addition, the recruitment 
and expansion of CD4
+CD25
+Tregs in MM patients in the 
suppression of tumor immunity has been reported [19, 20]. 
More recently, the discovery of MDSCs revealed these cells 
to be potent suppressors of tumor immunity and, therefore, 
a significant impediment to cancer immunotherapy [21]. 




low MDSCs and CD4
+FOXP3
+ Tregs cells was increased 
in MM patients at diagnosis and inhibited proliferation of 
both CD4
+ and CD8
+ T cells [22].
CURRENT DC-BASED VACCINES IN MM
Usually, ex vivo DCs are generated from circulating blood 
precursors (i.e., monocytes) or BM progenitor cells and are 
educated with tumor antigens prior to vaccination. Ex 
vivo-generated DCs can be loaded with myeloma-associated 
antigens as vaccines for patients with MM. The use of im-
mature DCs or mature DCs, method used to induce DC 
maturation, types of tumor antigens, techniques used to load 
tumor antigens onto DCs, routes of administration, and dos-
ing schedules are being investigated.
1. Idiotype-pulsed DCs
Immunoglobulin idiotype (Id) is a tumor-specific antigen 
t h a t  i s  p r o d u c e d  b y  e a c h  B  c e l l  t u m o r  c l o n e .  I d  p r o t e i n  
has been used for immunotherapy in patients with MM 
[23, 24]. Id vaccination could induce responses by both anti-
bodies and Id-specific T cells, including CD4
+ and CD8
+ 
T cells, through the presentation of Id protein on the surface 
of professional APCs. Id-specific CTL lines that kill autolo-
gous primary myeloma cells in vitro have been generated. 
In one report, killing activity was induced by only MHC 
class I-restriction [25], while another report described both 
class I- and class II-restriction [26]. Autologous DCs that 
were generated from MM patients have been shown to effi-
ciently endocytose different classes of Id proteins, and autolo-
gous Id-specific CTLs containing both CD4
+ and CD8
+ T 
cells that were generated by Id-pulsed DCs were able to 
recognize and kill autologous primary myeloma cells in vitro 
[26, 27]. Various studies of DC-based Id vaccination in MM 
have been reported [28-35]. Although Id-specific CTLs and 
immune responses could be induced in some patients, clinical 
responses have rarely been observed after vaccination [30], 
possibly because Id protein is a weak antigen and immature 
DCs have been used in some studies [28]. 
2. Myeloma-associated antigen-loaded DCs
A variety of myeloma-associated antigens that may induce 
immune responses from DC-based vaccines have been identi-Korean J Hematol 2012;47:17-27.
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fied in MM patients. Many potential tumor-associated anti-
gens (TAAs) in MM have been investigated, including poly-
morphic epithelial mucin (MUC1), human telomerase re-
verse transcriptase (hTERT), preferentially expressed antigen 
of myeloma (PRAME), Sperm protein 17 (Sp17), Wilms’ 
tumor-I (WTI), Dickkopf-1 (DKK-1), and members of the 
cancer germ-like family (MAGE, GAGE, BAGE, LAGE, and 
NY-ESO-1). MUC1 was expressed in all MM cell lines and 
primary myeloma cells. MUC1-specific CTLs that were in-
duced  in vitro using peptide-pulsed DCs or plasma cell 
RNA-loaded DCs efficiently killed not only target cells pulsed 
with the antigenic peptide but also MM cells [36, 37]. 
NY-ESO-1 is the most immunogenic of the cancer testis 
antigens, proteins that are expressed in a variety of tumors, 
but whose expression in normal tissue is limited to the testis 
and placenta [38]. Spontaneous humoral and CD8
+ T 
cell-mediated responses to NY-ESO-1 have been identified 
in patients with advanced disease [38]. In addition, in vitro 
monocyte-derived DCs transfected with PTD-NY-ESO-1 
protein can induce CD8
+ cellular antitumor immunity superi-
or to that achieved with NY-ESO-1 protein alone [39]. 
Sp17-specific HLA class I-restricted CTLs were successfully 
generated by DCs that had been loaded with recombinant 
Sp17 protein and were able to kill autologous tumor cells 
that expressed Sp17 [40]. The overexpression of hTERT on 
MM compared to the expression levels in normal cells in-
dicated that this telomerase also could be used as a myelo-
ma-associated antigen. hTERT was capable of triggering anti-
tumor-CTL responses and killing hTERT
+ tumor cells [41]. 
Recently, a report demonstrated that activated T lympho-
cytes were able to successfully kill myeloma cells after stim-
ulation by DCs loaded with hTERT- and MUC1-derived 
nonapeptides [42]. DKK1, a novel protein that is not ex-
pressed in most normal tissues but is expressed in almost 
all myeloma cells, may be an important antigenic target 
for antimyeloma immunotherapy. DKK1-specific CTLs that 
were generated by DCs pulsed with DKK1 peptides were 
specifically lysed by autologous primary myeloma cells and 
DKK1-positive cell lines [43]. In general, DCs loaded with 
TAAs may be promising agents for use in immunotherapy 
against MM.
3. Whole tumor antigen-loaded DCs
Although a single TAA can induce antitumor immune 
response against MM, tumors may escape immune recog-
nition via down-regulation of specific antigen expression. 
In contrast, DCs loaded with antigens derived from whole 
tumor cells can improve the antitumor response, limiting 
the risk of immunological escape. Numerous reports have 
described these alternative approaches, such as DCs pulsed 
with myeloma lysates [44, 45], DCs pulsed with myeloma 
apoptotic bodies [46, 47], DCs transfected with myelo-
ma-derived RNA [37], DCs pulsed with myeloma-derived 
heat shock protein (HSP) gp96 [48, 49], and DC-myeloma 
cell hybrids [50, 51]. These techniques have the advantage 
of allowing the presentation of multiple epitopes to MHC 
on DCs, therefore inducing polyclonal T cell responses from 
many potentially unknown TAAs and reducing the proba-
bility of immune escape by a single TAA. DCs loaded with 
myeloma cell lysates induced much more potent cytotoxicity 
in autologous plasma cells than Id protein-pulsed DCs did, 
suggesting the superiority of the myeloma cell as a source 
of a tumor antigen [45]. The apoptotic bodies derived from 
myeloma cells have also been used as tumor antigens for 
loading onto DCs. Interestingly, these apoptotic bodies were 
shown to be more effective than cell lysates at inducing 
CTLs against autologous myeloma cells [52]. HSPs are a class 
of functionally related proteins whose expression is increased 
when cells are exposed to elevated temperatures or other 
stresses. Tumor-derived HSPs, such as HSP70 and gp96, are 
immunogenic, potent stimulators of tumor-specific CTLs. 
The specific CTLs that were stimulated by myeloma-derived 
gp96-loaded DCs were able to lyse myeloma cells but not 
normal blood cells in a MHC class I-restricted manner [48, 
49]. Moreover, fusion of autologous DCs with patient-derived 
tumors stimulated both helper and cytotoxic T cell responses 
through the presentation of internalized and newly synthe-
sized antigens [51]. In mouse MM models, vaccination with 
DCs fused with either plasmacytoma cells or tumor cells 
resulted in eradication of tumors and protective immunity 
against subsequent tumor challenge [50]. In general, the 
production of DC vaccines using whole tumor antigens has 
become a promising tool for immunotherapy against MM. 
CLINICAL USES OF DC-BASED VACCINES FOR MM
Trial protocols and responses are summarized in Table 
1. Clinical trials of DC-based vaccines for MM have been 
restricted until now. Almost all of these clinical trials used 
Id-pulsed DCs alone or in combination with adjuvants such 
as cytokines or KLH. Recently, a phase I study was under-
taken, in which patients with MM were vaccinated with 
an autologous DC/tumor cell fusion in combination with 
granulocyte-macrophage colony-stimulating factor (GM- 
CSF) administration [53]. A commercial product is currently 
being tested in a phase III trial (Mylovenge
TM, Dendreon 
Corp., Seattle, WA, USA). Mylovenge (APC8020) is con-
ducted by pulsing autologous DCs with the patient’s Id. A 
recent report describing this commercial product showed 
the long-term survival of those receiving the vaccine in 
comparison with the survival of all other patients with MM 
who underwent autologous HSCT [54].
HOW DC-BASED VACCINES IN 
MM CAN BE IMPROVED
The goal of DC-based vaccines in cancer immunotherapy 
is to induce the expansion of tumor-specific T cells and 
establish immune responses. Cellular immunotherapy using 
DC-based vaccines have been used as therapeutic agents 
in MM patients; however, few patients experienced tumor 
regression, and the most common responses to current DC Korean J Hematol 2012;47:17-27.
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Table 1. Summary of clinical studies using DC-based vaccinations.
Author  DC type  TA Adjuvant Immune responses  Clinical responses 
Liso et al. [29] imDC  Id  ± KLH  4/24 Id-specific  17/26 SD 
Lim et al. [28] imMo-DC  Id  KLH  5/6 Id-specific; 2/6 Id-specific IFN-γ; 3/6 increase 
in Id-specific CTL frequency
6/6 PD 
Reichardt et al. 
[32]
imDC  Id  None  2/12 Id-specific proliferation; 1/3 Id-specific CTL  2 relapse; 8/10 PD; 2/10 SD 
Titzer et al. [30] CD34-DC  Id  None  4/10 Id-specific T cell proliferation; 1/10 
decreased BM plasmacytosis 
1/10 SD; 9/10 PD 
Cull et al. [89] imMo-DC  Id  None  2/2 Id-specific T cell proliferation; no Id-specific 
CTL response 
2/2 PD 
Yi et al. [31] mMo-DC  Id  IL-2  2/5 Id-specific T cell proliferation; 5/5 Id-specific B 
cell proliferation; 4/5 Id-specific IFN-γ 
1/3 PR; 3/5 SD; 1/5 PD 
Bendandi et al. 
[33]
mMo-DC  Id  None  4/4 anti-KLH response; 2/4 Th1 cytokines 
response 
1/4 SD; 3/4 PD 
Lacy et al. [54] APC8020 
(Mylovenge) 
Id  None  None reported  6/26 CR; 2/26 PR; 19/27 SD 
Overall survival: 5.3 years of 
follow-up for surviving patients 
Yi et al. [34] CD40 L-DCs  Id  KLH  9/9 Id-specific IFN-γ; 5/9 Id-specific CTL response; 
8/9 anti-KLH response 
6/9 SD; 3/9 slowly PD 
4/6 continue SD after 5 years 




GM-CSF  11/15 CD4 and CD8 response with autologous 
myeloma cells; 5/5 tested anti-MUC1 response 
11/16 SD (3/11＞1 year SD; 8/11 
2.5-5 month SD) 
Röllig et al. [35] mMo-DC  Id  KLH  5/9 Id-specific T cell proliferation; 8/9 Id-specific 
cytokines response
3/9 M protein decrease; 5/9 M 
protein stable 
Abbreviations: DC, dendritic cell; TA, tumor antigen; imDC, immature DC; Mo-DC, monocyte-derived DC; Id, idiotype; mMo-DC, mature 
Mo-DC; KLH, keyhole limpet hemocyanin; CTL, cytotoxic T lymphocyte; PD, progressive disease; PR, partial response; SD, stable disease; CR,
complete response.
Fig. 1. Key points to improve DC vaccination in cancer patients. Abbreviations: CTL, cytotoxic T lymphocyte; DCs, dendritic cells; TA, tumor antigen;
LNs, lymph nodes; Treg, regulatory T cell; MDSC, myeloid-derived suppressor cell.Korean J Hematol 2012;47:17-27.
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vaccines are only antigen-specific immune responses. This 
is required in a new strategy for the treatment of cancer, 
in which the intrinsic abilities of the immune system re-
sponse to the DC-based vaccine has been modified to enhance 
the efficacy of vaccination. In particular, DCs in MM patients 
are a target of tumor-associated suppressive factors from 
the microenvironment, since ex vivo DCs, which are usually 
generated from patients, are functionally defective, resulting 
in their suppressed ability to support effector functions in 
tumor-specific immune responses [12, 13]. In the generation 
of DCs, the effects of several immunosuppressive factors 
in the tumor microenvironment, including the production 
of inhibitory cytokines, activation of STAT3, expansion of 
Tregs, and significant suppressive effects of MDSCs, have 
been investigated. Therefore, the recent focus has been on 
improving the efficacy of DC vaccines against tumors (Fig. 
1).
1. α-type 1-polarized DCs as highly potent inducers of CTLs 
against cancers
The initial success of DC-based vaccines involving im-
mature or partially-mature “first-generation” DCs has been 
reported [55, 56]. The first therapeutic DC-based cancer 
vaccine against prostate cancer (Sipuleucel-T/Provenge) re-
ceived US FDA approval and demonstrated the ability of 
the vaccine to prolong overall survival in patients with highly 
advanced cancer [57]. However, such DCs express suboptimal 
levels of costimulatory molecules and constitute weaker im-
munogens than subsequently implemented mature DCs, the 
“second generation” of clinically applied standard DCs 
(sDCs). sDC vaccines induced by cytokine cocktails contain-
ing IL-1β/TNF-α/IL-6/prostaglandin E2 (PGE2) have been 
developed [58]. Such DCs are fully mature and exhibit in-
creased expression costimulatory molecules and CCR7 and 
high migratory responsiveness to lymph node-associated 
chemokines; they have been widely tested in clinical trials. 
However, to date, sDC vaccines still have limitations, includ-
ing the mediation of Th2 polarization, promotion of secretion 
of the immunosuppressive cytokine IL-10 from DCs, inability 
to induce the Th1-type response (because PGE2 abolishes 
the secretion of IL-12p70), and high activity of such DCs 
in activating Tregs [59, 60]. In addition, the induction of 
antitumor CTL responses by DC-based vaccines benefits from 
high expression of costimulatory molecules, CCR7 re-
sponsiveness, and migration in response to lymphoid chemo-
kines from mature DCs [61]. At the same time, high IL-12p70 
secretion has been shown to dramatically enhance the ability 
of DCs to induce tumor-specific Th1 cells and CTLs and 
to promote tumor rejection in therapeutic mouse models 
[62]. Unfortunately, both first- and second-generation DCs 
were unable to induce effective CTL responses. Therefore, 
several investigators, including our group, have tried to de-
velop potent DCs that possess all required features for induc-
ing effective tumor-specific immune responses. We demon-
strated the feasibility of inducing mature but “nonexhausted” 
DCs, by exposing immature DCs to type 1 and type 2 interfer-
ons (IFNs) combined with TNFα or Toll-like receptor (TLR) 
ligands. In particular, α-type 1-polarized DCs (αDC1s) that 
have been induced to mature using an αDC1-inducing cyto-
kine cocktail containing IL-1β, TNF-α, IFN-α, IFN-γ, and 
polyinosinic:polycytidylic acid [poly(I:C)] have been devel-
oped to generate strong functional CTLs in several diseases 
and are on average 20-fold higher than sDCs [63, 64]. The 
resulting  αDC1s showed high expression of several cos-
timulatory molecules or high secretion of IL-12p70, improv-
ing the induction of tumor-specific and functional CTLs 
in comparison with that in sDCs in vitro and in vivo [64-67]. 
Recently, we successfully generated αDC1s from MM pa-
tients with high expression of costimulatory molecules, sig-
nificant production of IL-12p70, and potent generation of 
myeloma-specific CTLs [46, 47]. Such a novel strategy would 
provide improved potency of ex vivo-generated DCs for can-
cer therapy.
2. Natural killer (NK) cells as helpers cells during induction 
of type-1 immunity by DCs
The other strategy to induce potent DCs from patients 
with MM was the use of helper cells to promote type 1-polar-
ization of DCs. NK cells rapidly migrate to sites of infection 
and control the immune response in viral infections. Indeed, 
it has been demonstrated that NK cells play a major immunor-
egulatory role in the development of protective T cell-medi-
ated immunity against intracellular pathogens and cancers 
[68]. Such helper activity of NK cells is at least partially 
mediated by the functional modulation of DCs. This phenom-
enon depended on the production of IFN-γ and TNF-α by 
activated NK cells [68] and was associated with enhanced 
tumor antigen cross-presentation and the induction of Th1 
and CTL responses [69-71]. Recent data from our laboratory 
and other groups has demonstrated that such NK-DC inter-
actions promote the subsequent induction of tumor-specific 
responses in CD4
+ and CD8
+ T cells, allowing NK cells to 
act as helper cells in the development of type-1 polarized 
DCs in responses against cancer [69-71]. Resting NK cells 
that are activated in the presence of TLR agonists, IL-2, 
and IFN-α can induce potent DCs with enhanced IL-12p70 
production  in vitro, generating stronger functional CTLs 
against myeloma cells than sDCs [71].
3. Combination of IFN and TLR agonists induce potent type-1 
polarized DCs
We also found that the selected combinations of TLR 
agonists synergistically triggered a Th1-polarizing capacity 
through production of high amounts of IL-12p70 [72]. 
However, the major limitation of this combination was the 
decreased ability of these cells to migrate into lymph nodes 
compared to that of conventional DCs. When DCs are acti-
vated by individual TLR agonists, such as LPS or poly(I:C), 
or by a combination of 2 TLR agonists, all cells mature 
and produce high levels of bioactive IL-12p70 in early phase 
of maturation and after subsequent stimulation with T 
cell-related DC activating signal CD40L. In addition, the 
phenotyes of these matured DCs were markedly enhanced 
when a combination of type I and type II IFN was added. Korean J Hematol 2012;47:17-27.
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These combinations of stimuli also regulated the expression 
of CD38 and CD74, markers related to the full activation 
of DCs [73, 74]. We demonstrated that at the optimal concen-
tration used to stimulate DCs, the combination of 2 TLR 
agonists with type I and II IFNs can be used to generate 
fully mature DCs that have high migratory capacity and 
can maintain IL-12p70-producing capacity. The regulation 
of CD38 and CD74 in DCs could in turn enhance the mi-
gratory activity of DCs in the presence of a combination 
of 2 TLR agonists and IFNs [75].
4. Type-1 immunity induced by DCs maturated using natural 
products of TLR signaling
Ursolic acid (URC) is isolated from Uncaria rhynchophylla 
and phytochemically classified as a triterpene. Triterpene 
compounds have been identified as a unique class of natural 
products possessing diverse biological activities. Recently, 
we reported that URC activates human DCs in a fashion 
that favors Th1 polarization via the activation of TLR2- 
and/or TLR40 dependent IL-12p70 and induces the pro-
duction of IFN-γ by CD4
+ naïve T cells [76]. In addition, 
combination URC and IFN-γ enhanced the activation of DCs 
via promotion of IFN-γ-induced Th1-cell polarization that 
was dependent on the activation of IL-12p70 and in-
dependent of TLR4 [77]. The potential of natural products 
to enhance DC maturation and activation has important im-
plications for the use of DCs as cancer vaccines.
5. Enhancement of cross-presentation of DCs by tumor-asso-
ciated antigens
The clinical responses of DC vaccines using Id-pulsed DCs 
have been disappointing. The use of TAAs can induce more 
significant immune responses than Id. Although a single 
TAA can induce antitumor immune responses against MM, 
tumors may escape immune recognition via down-regulation 
of specific antigen expression. In addition, only a small num-
ber of tumor samples from MM patients showed a similar 
level of TAA expression, limiting the usefulness of TAAs 
in MM. Therefore, to overcome the effects of TAA-based 
immunotherapy, our group has attempted to use other tumor 
antigens that improve the cross-presentation of the DC vac-
cine in patients with MM.
The selected antigen should possess the best characteristics 
for induction of cross-presentation and should be tumor spe-
cific and easily available, but should not induce immune 
suppression. Whole tumor antigens, including myeloma cell 
lysates and apoptotic bodies from myeloma cells, are the 
best tumor antigens and have been selected by many 
investigators. In practical terms, a number of patients with 
MM have less than 50% myeloma cells in the BM at diagnosis 
or during progression of the disease. When mononuclear 
cells from the BM are used as a source of tumor antigens, 
contamination with normal cells, especially lymphocytes, 
may occur. Thus, it is necessary to use purified, optimized 
myeloma cells, if possible, as a source of tumor antigens 
for the generation of myeloma-specific CTLs stimulated by 
DCs [44]. We have shown that the function of DCs was 
affected by the concentration of myeloma cell lysates (i.e., 
higher concentrations of lysates suppressed T cell stimulatory 
capacities) [44]. CTLs that were generated by purified, opti-
mized myeloma cell lysates pulsed with DCs demonstrated 
much stronger cytotoxicity against autologous plasma cells. 
These findings indicate that it is important to optimize the 
concentration of myeloma cell lysates that were loaded onto 
DCs to potentiate their function.
The use of whole tumor cells instead of single antigens 
may enhance antitumor effects, but may also target multiple 
tumor variants and counteract tumor immune evasion. 
However, it is impractical to obtain sufficient amounts of 
purified autologous myeloma cells for tumor antigens in 
the clinical setting of MM. As an alternative source of tu-
mor-relevant antigens, allogeneic tumor cells or established 
cancer cell lines have been used to overcome this limitation 
in various tumors [46, 47]. In clinical practice, allogeneic 
myeloma cell lines may be an effective source of universal 
tumor antigens that could be used to load DCs for the gen-
eration of myeloma-specific CTLs in MM patients. Tumor 
antigens derived from DC-loaded irradiated allogeneic mye-
loma cells could generate myeloma-specific CTLs against 
autologous myeloma cells in patients with MM [46, 71]. 
The success of using an allogeneic myeloma cell line as tumor 
antigens led to the possibility that allogeneic myeloma cells 
could also be used as a viable source of tumor antigens in 
the context of appropriate major MHC alleles to autologous 
CTLs. We investigated the possibility of using autologous 
DCs loaded with an apoptotic allogeneic matched mono-
clonal immunoglobulin subtype of myeloma and showed 
that the CTL generated by these tumor antigen-loaded DCs 
could generate myeloma-specific CTLs against autologous 
myeloma cells in MM patients [47]. These findings suggested 
that allogeneic myeloma cell lines and allogeneic matched 
monoclonal immunoglobulin subtype of myeloma were ef-
fective tumor antigens capable of inducing functional CTLs 
against patients’ own myeloma cells.
6. Blocking immunosuppressive activity during tumor anti-
gen loading
T h e  s u p p r e s s i v e  e f f e c t s  o f  t u m o r  c e l l s  d u r i n g  D C  g e n -
eration have been explained previously by the ability of 
the tumor microenvironment to suppress DC differentiation 
[78]. This suppression is due to the activation of STAT3 
and the production of immunosuppressive factors. These fac-
tors can influence STAT3 and extracellular signal-regulated 
kinase (ERK) phosphorylation, resulting in hyperactivation 
of STAT3 and ERK, which may be responsible for defective 
DC differentiation [79]. In addition to generate potent and 
specific tumor antigen-loaded DCs for vaccination, alter-
native methods have attempted to restore defective DC func-
tion and to enhance DC function in MM. The immune-medi-
ated antitumor effects of DCs are enhanced by inhibition 
of the janus-activated kinase 2 (JAK2)/STAT3 pathway [80], 
inhibition of p38 or activation of the MEK/ERK or mi-
togen-activated protein kinase (MAPK) pathways, and neu-
tralization of IL-6 [81]. Recently, we found that when Korean J Hematol 2012;47:17-27.
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MM-specific DCs were generated by loading tumor lysates 
from myeloma cells collected at diagnosis or during the re-
lapsed/progressive state, these DCs showed lower phenotypic 
maturation, less T cell stimulatory capacity, less CTL activity, 
and highly abnormal IL-6 and IL-12 secretion compared 
to the secretion by unloaded DCs. Moreover, the levels of 
VEGF, phospho-STAT3, and phospho-ERK1/2 in DCs were 
significantly higher than in unloaded DCs. After neutraliza-
tion of VEGF activity, DC functions, signal transduction, 
and cytokine production returned to normal. Therefore, in-
hibitory factors and abnormal signaling pathways during 
maturation with tumor antigens in DCs may be responsible 
for the defective activity of DCs in MM, and these abnormal-
ities may be overcome by neutralizing the signaling that 
would lead to a suppressed immune response [82]. Currently, 
we are working to develop strategies that recover dysfunction 
of DCs caused from loading tumor antigens through treat-
ment of myeloma cells with a combination of the selective 
JAK/STAT3 inhibitor JSI-124 and proteasome inhibitor 
bortezomib. We observed that production of inhibitory cyto-
kines, such as IL-10, IL-23, and especially IL-6, which is 
known as the main plasma cell growth factor that induces 
DC dysfunction in MM patients, was down-regulated in DCs 
loaded with JSI-124- and bortezomib-induced dying myelo-
ma tumor cells. Furthermore, phospho-STAT3 was also 
down-regulated in these DCs. Consistent with their recovery 
functions, these DCs displayed a superior ability to induce 
myeloma-specific responses of CTLs (unpublished data). We 
found that pretreatment of myeloma cells with a combination 
of JSI-124 and bortezomib recovered DC dysfunction caused 
by loading of dying myeloma cells through the up-regulation 
of Hsp90 and down-regulation of STAT3 phosphorylation 
and inhibitory cytokine production. These DCs could gen-
erate potent myeloma-specific CTLs.
7. Regulation of the migratory patterns of DCs
In vitro-generated DCs that are used for targeting local 
lymph nodes in vaccination protocols are highly sought after, 
but difficult to achieve in practice. Type 1-polarized DCs 
with higher levels of IL-12p70 and potent CTL generation 
targeting are limited by their migratory capacity to primary 
lymph nodes due to the relatively lower expression of CCR7 
in these DCs than in sDCs. The first important mediator 
in  th e mo bilizat io n o f  DC s to  l ymph  no des is CC R7. Ho wever, 
upregulation of CCR7 alone is insufficient to drive DC migra-
tion toward CCL19 and CCL21. Up-regulation of CD38 and 
down-regulation of CD74 regulate DC migration in vitro 
and in vivo [73, 74]. We recently reported that the migratory 
capacity of DCs is enhanced by the regulation of CD38, 
CD74, and CCR7 expression on DCs, resulting from the 
TLR-agonist-mediated synergistic effects of type I and II 
IFNs on the regulation of DC migration and providing a 
novel approach to improving vaccination efficacy [75].
The efficacies of 3 features, namely, fully mature status, 
high migratory responsiveness t o  l y m p h - n o d e  a s s o c i a t e d  
chemokines (CCR7 ligands), and ability to produce high 
levels of IL-12p70, determine whether DCs are appropriate 
carriers for anticancer vaccines [63]. However, although 
α-type 1-polarized DCs possess all of the above features, 
the expression of CCR7 and the migration of DCs in response 
to the CCR7 ligand (CCL19 and CCL21) were lower in these 
DCs than in conventional sDCs [63, 64] due to the lack 
of PGE2, a critical component of the standard cytokine cock-
tail that is important for the expression of CCR7 and the 
responsiveness of DCs to CCR7 ligands [83]. We also inves-
tigated whether migration could be enhanced by increasing 
the expression of CCR7 or the migration of DCs and found 
that after stimulation of monocyte-derived DCs by CCL21 
2 hr before the end of maturation by α-type 1-polarized 
cytokine cocktail, the migration of harvested DCs through 
transwells was faster than that of unstimulated DCs. Interest-
ingly, phenotypes and cytokine production levels were sim-
ilar in both DCs. Furthermore, we also found that CCL21- 
treated DCs could induce the ability to stimulate tumor- 
specific responses of CTLs by the enhancement of CXCL10 
(IP-10) secretion (unpublished data). We are now investigat-
ing this phenomenon to generate monocyte-derived DCs 
in MM patients and in vivo mouse models.
8. Regulation of the suppressive environment
Therapeutic DC vaccines need to be highly effective at 
inducing the expansion of tumor-specific T cells and need 
to avoid interaction with and induction of immunosuppressor 
cells, such as Tregs and MDSCs. Recently, type 1-polarized 
DCs were shown to suppress the secretion of CCL22 (Treg- 
and Th2-type attracting chemokines), enhance the secretion 
of CCL5 and CXCL10 (Th1- and effector T cell-attracting 
chemokines), and suppress the induction of Tregs compared 
to sDCs [84]. In addition, to enhance the antitumor effects 
of DC-based vaccines in preclinical in vivo mouse models, 
we have developed several models of combination therapy 
using DCs and immunomodulatory drugs, including cyclo-
phosphamide and lenalidomide. Cyclophosphamide is fre-
quently used to enhance or augment antitumor effects in 
cancer immunotherapy [85]. Low-dose cyclophosphamide 
may enhance the antitumor efficacy of DC vaccines by in-
creasing the proportion of IFN-γ secreting lymphocytes and 
suppressing the proportion of CD4
+CD25
+FoxP3
+ Tregs in 
tumor-bearing mice [85]. The result of a clinical trial using 
a l l o g e n e i c  D C  v a c c i n e s  c o m b i n e d  w i t h  l o w - d o s e  c y c l o -
phosphamide has revealed that the combination therapy 
could induce stronger antitumor responses compared to the 
DC vaccine alone [86]. Recently, we developed a cancer 
model of combination therapy in mice showing that a single 
administration of low-dose cyclophosphamide before the 
first DC vaccination augmented the antitumor effects of DC 
vaccines to completely eradicate the tumor, prolonging the 
survival of vaccinated mice [70]. 
We are developing a mouse myeloma combination therapy 
model, in which the myeloma tumor-bearing mice were 
vaccinated with a combination of DCs and lenalidomide. 
Lenalidomide is a thalidomide analog that is more potent 
and has less adverse effects [11]. Lenalidomide can induce 
apoptosis; inhibit the production of cytokines (IL-6, VEGF, Korean J Hematol 2012;47:17-27.
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and TNF-α) in BM; and stimulate T cell and NK cell pro-
liferation, cytotoxicity, and cytokine (IL-2, IFN-γ) pro-
duction [11]. In addition, lenalidomide can inhibit the fre-
quency and function of Tregs, resulting in inhibition of Treg 
expansion and forkehad box P3 (FOXP3) expression in cancer 
patients [87]. Interestingly, this drug can also induce the 
activation of APC function, resulting in upregulation of 
CD40, CD80, and CD86, in chronic lymphocytic leukemia 
[88]. Therefore, lenalidomide could be used as an immuno-
modulatory drug in order to enhance immune responses 
against cancer. Our in vitro study showed that lenalidomide 
enhanced the maturation and function of DCs in synergistic 
stimulation with LPS to increase phenotype expression, 
IL-12p70 production, T cell stimulation capacities, and cyto-
toxic activities against myeloma cells. In addition, lenalido-
mide combined with LPS induced type 1-polarization of 
naïve T cells and suppressed the generation of Tregs 
(unpublished data). Moreover, our in vivo mouse myeloma 
model showed that a treatment combining the immunomod-
ulatory drug lenalidomide with a DCs vaccine improved 
antitumor immunity by inhibiting immunosuppressor cells 
and recovering effector cells and inducing superior polar-
ization of the Th1/Th2 balance in favor of the Th1 response. 
This immunomodulatory effect may be a crucial component 
of the enhancer-like properties of lenalidomide in the context 
of antitumor immunity against MM (unpublished data).
FUTURE PERSPECTIVES
Despite their limitations, recent clinical studies have sug-
gested that DC-based vaccinations may be potential therapies 
that induce tumor responses and prolong the survival of 
patients with MM. Further investigations are needed to in-
crease DC-based potency and improve immune responses, 
and these investigations should focus on the identification 
of alternative tumor antigens uniquely or specifically ex-
pressed on myeloma cells, recovery or restoration of the 
dysfunction of DCs in MM patients, induction of T cells 
with desirable effector functions rather than regulatory func-
tions, migration into lymph nodes to stimulate T cells, and 
clarification of the ability of tumor-specific CTLs to recognize 
and kill tumor cells. We expect that type 1-polarized DCs 
can be developed to generate strong functional myeloma-spe-
cific CTLs. Allogeneic myeloma cell lines or allogeneic mye-
loma cells may be an effective source of universal tumor 
antigens that could be used to load to DCs for the successful 
generation of myeloma-specific CTLs. Eventually, combina-
tion therapy, in which a DC vaccine is combined with either 
alternative therapy, including chemotherapy, radiation ther-
apy, molecular target therapy, or other immunotherapy 
(adoptive T cell therapy, NK cell therapy, etc.), or with 
an adjuvant, will provide vigorous and maintained immune 
responses with improved clinical efficacy.
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